Walleye Capital LLC Takes $2.27 Million Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Walleye Capital LLC bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the 4th quarter, Holdings Channel reports. The institutional investor bought 267,743 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,268,000.

Several other institutional investors and hedge funds also recently made changes to their positions in KALV. Legal & General Group Plc grew its stake in shares of KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares in the last quarter. Martin Worley Group bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at about $86,000. China Universal Asset Management Co. Ltd. lifted its holdings in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 1,319 shares in the last quarter. Finally, Intech Investment Management LLC raised its stake in KalVista Pharmaceuticals by 58.5% in the 4th quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company’s stock worth $146,000 after purchasing an additional 6,349 shares in the last quarter.

Wall Street Analyst Weigh In

KALV has been the subject of a number of recent analyst reports. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. TD Cowen started coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. Jones Trading reissued a “buy” rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ KALV opened at $12.00 on Friday. The firm has a market capitalization of $596.59 million, a P/E ratio of -3.30 and a beta of 0.39. The firm’s 50-day moving average price is $11.32 and its 200-day moving average price is $10.33. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the stock in a transaction on Wednesday, April 9th. The shares were purchased at an average price of $9.42 per share, for a total transaction of $235,500.00. Following the completion of the acquisition, the insider now owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. This represents a 0.47 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares in the company, valued at $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have bought 261,055 shares of company stock valued at $2,397,646 and have sold 17,292 shares valued at $184,625. 10.50% of the stock is owned by company insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).